[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Horta R, Barreto F, Marques M, Rebelo M, Reis JC, Lopes JM, Amarante JM: Epithelial-myoepithelial parotid carcinoma after kidney transplantation. Ecancermedicalscience; 2008;2:92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial-myoepithelial parotid carcinoma after kidney transplantation.
  • The occurrence of a second malignant neoplasm (SMN) in patients who have been submitted to kidney transplantation is increasing and causes concern; parotid carcinoma is rarely reported after transplantation and may be related to long-term chemotherapy.Salivary gland carcinomas displaying exclusively myoepithelial differentiation-myoepithelial carcinomas (EMC) are rare, being less than 1% of all salivary gland tumours.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275975.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234068
  •  go-up   go-down


2. Shi H, Wang J, Dong F, Wang X, Li H, Hou Y: The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma. BMC Cancer; 2009;9:456
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of proteoglycans inhibited by RNA interference on metastatic characters of human salivary adenoid cystic carcinoma.
  • BACKGROUND: Salivary adenoid cystic carcinoma (SACC) is one of the most common malignancies of salivary gland.
  • In SACC, neoplastic myoepithelial cells secrete proteoglycans unconventionally full of the cribriform or tubular and glandular structures of SACC.
  • This research could provide a new idea for the clinical treatment of SACC.
  • The XTLY-I expression was measured by real-time PCR and Western blot; the reduction of proteoglycans was measured.
  • [MeSH-major] Carcinoma, Adenoid Cystic / drug therapy. Pentosyltransferases / antagonists & inhibitors. Proteoglycans / antagonists & inhibitors. RNA, Small Interfering / pharmacology. Salivary Gland Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Base Sequence. Female. Gene Expression Regulation, Neoplastic / drug effects. Gene Knockdown Techniques. Gene Targeting. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. NIH 3T3 Cells. Neoplasm Metastasis. RNA Interference / physiology. Tumor Cells, Cultured. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Adenoid Cystic Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):948-58 [11959843.001]
  • [Cites] IUBMB Life. 2002 Oct;54(4):163-75 [12512855.001]
  • [Cites] Exp Mol Pathol. 2003 Apr;74(2):113-22 [12710942.001]
  • [Cites] Ann Biomed Eng. 2004 Jan;32(1):50-6 [14964721.001]
  • [Cites] Cell Mol Life Sci. 2004 Apr;61(7-8):794-809 [15095004.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2004 Apr;12(2):127-32 [15167050.001]
  • [Cites] J Pathol. 2004 Aug;203(4):953-60 [15258999.001]
  • [Cites] Cancer Metastasis Rev. 1988 Jun;7(2):143-88 [3293836.001]
  • [Cites] Arch Pathol Lab Med. 1990 Dec;114(12):1227-31 [2174671.001]
  • [Cites] Annu Rev Biochem. 1991;60:443-75 [1883201.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s [1884381.001]
  • [Cites] Am J Pathol. 1992 Aug;141(2):467-74 [1379782.001]
  • [Cites] Biotechnology (N Y). 1993 Sep;11(9):1026-30 [7764001.001]
  • [Cites] Int J Oral Maxillofac Surg. 1995 Apr;24(2):153-7 [7608581.001]
  • [Cites] Virchows Arch. 1995;426(6):577-86 [7655738.001]
  • [Cites] Lab Invest. 1996 Apr;74(4):781-96 [8606488.001]
  • [Cites] Zhonghua Kou Qiang Yi Xue Za Zhi. 1995 Jul;30(4):215-7, 256 [8745443.001]
  • [Cites] J Oral Pathol Med. 1996 Sep;25(8):441-8 [8930823.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):495-8 [9374223.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2679-88 [9531576.001]
  • [Cites] Annu Rev Biochem. 1998;67:609-52 [9759499.001]
  • [Cites] J Oral Pathol Med. 1999 Jan;28(1):37-42 [9890456.001]
  • [Cites] J Biochem. 1999 Feb;125(2):406-13 [9990141.001]
  • [Cites] Otolaryngol Clin North Am. 1999 Oct;32(5):919-43 [10477796.001]
  • [Cites] Nature. 2004 Nov 11;432(7014):173-8 [15538359.001]
  • [Cites] Biochem J. 2005 Mar 1;386(Pt 2):227-36 [15461586.001]
  • [Cites] J Biomed Mater Res A. 2005 Dec 1;75(3):733-41 [16110495.001]
  • [Cites] J Mol Med (Berl). 2005 Dec;83(12):984-92 [16133423.001]
  • [Cites] Biochem J. 2006 Feb 15;394(Pt 1):163-71 [16225459.001]
  • [Cites] J Biol Chem. 2006 May 19;281(20):14224-31 [16569644.001]
  • [Cites] Acta Histochem. 2006;108(4):259-64 [16899283.001]
  • [Cites] Clin Chem. 2006 Dec;52(12):2243-9 [17040958.001]
  • [Cites] Oral Oncol. 2007 Nov;43(10):987-98 [17257887.001]
  • [Cites] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2007 Nov;23(11):1028-30 [17988584.001]
  • [Cites] Expert Opin Ther Targets. 2008 Jan;12(1):115-27 [18076375.001]
  • [Cites] Biochem Biophys Res Commun. 2008 May 23;370(1):123-8 [18355439.001]
  • [Cites] Hua Xi Kou Qiang Yi Xue Za Zhi. 2008 Apr;26(2):206-10 [18605467.001]
  • [Cites] BMC Cancer. 2008;8:185 [18590537.001]
  • [Cites] Acta Derm Venereol. 2000 Jan-Feb;80(1):60-1 [10721843.001]
  • [Cites] Oral Oncol. 2000 Mar;36(2):248-52 [10745180.001]
  • [Cites] Glycobiology. 2000 Jul;10(7):715-26 [10910975.001]
  • [Cites] Virchows Arch. 2000 Aug;437(2):122-8 [10993271.001]
  • [Cites] Glycobiology. 2000 Nov;10(11):1147-56 [11087707.001]
  • [Cites] J Mol Biol. 2000 Dec 8;304(4):517-28 [11099377.001]
  • [Cites] Biochem J. 2001 Apr 15;355(Pt 2):517-27 [11284741.001]
  • [Cites] J Clin Invest. 2001 Aug;108(3):349-55 [11489925.001]
  • [Cites] Biochem J. 2001 Oct 1;359(Pt 1):153-63 [11563979.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1443-8 [11818553.001]
  • [Cites] Nat Biotechnol. 2002 May;20(5):446-8 [11981553.001]
  • (PMID = 20025737.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Proteoglycans; 0 / RNA, Small Interfering; EC 2.4.2.- / Pentosyltransferases; EC 2.4.2.26 / UDP xylose-protein xylosyltransferase
  • [Other-IDs] NLM/ PMC2805682
  •  go-up   go-down


3. Jakacki RI, Hamilton M, Gilbertson RJ, Blaney SM, Tersak J, Krailo MD, Ingle AM, Voss SD, Dancey JE, Adamson PC: Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol; 2008 Oct 20;26(30):4921-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors.
  • An oral erlotinib solution was administered during the dose-finding phase and a tablet formulation was subsequently studied at the maximum-tolerated dose (MTD).
  • At 110 mg/m(2)/d, two of four patients had dose-limiting toxicity (DLT) consisting of rash and hyperbilirubinemia, whereas one of six patients developed dose-limiting rash at 85 mg/m(2)/d.
  • One patient with a neurocytoma had stable disease for 19 months, two patients with neuroblastoma remained on study for 23 and 24 months, and one patient with myoepithelioma had a mixed response.
  • CONCLUSION: The recommended phase II dose of erlotinib in recurrent pediatric solid tumors is 85 mg/m(2)/d, either alone or in combination with temozolomide.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Cancer. 2007 Oct 1;110(7):1542-50 [17705175.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):2053-63 [10815932.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6841-5 [11156376.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3267-79 [11432895.001]
  • [Cites] Anticancer Drugs. 2004 Jun;15(5):503-12 [15166626.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2853-7 [7796412.001]
  • [Cites] Cancer Res. 1996 Sep 1;56(17):3898-901 [8752155.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4838-48 [9354447.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Feb 24;255(3):774-7 [10049786.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1786-92 [10430083.001]
  • [Cites] Pharmacol Ther. 1999 May-Jun;82(2-3):241-50 [10454201.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Oncologist. 2005 Aug;10(7):508-17 [16079318.001]
  • [Cites] J Clin Oncol. 2005 Sep 1;23(25):5892-9 [16043829.001]
  • [Cites] BMC Cancer. 2005;5:131 [16219105.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):67-78 [16443950.001]
  • [Cites] Drug Metab Dispos. 2006 Mar;34(3):420-6 [16381666.001]
  • [Cites] Clin Pharmacol Ther. 2006 Aug;80(2):136-45 [16890575.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5259-64 [17114659.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):69-82 [17222791.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1228-38 [17283159.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1960-6 [17452677.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3913-21 [17606725.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):998-1007 [10741727.001]
  • (PMID = 18794549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / UL1 TR000005; United States / NCI NIH HHS / CA / CA97452; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Quinazolines; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2652086
  •  go-up   go-down


Advertisement
4. Savage K, Lambros MB, Robertson D, Jones RL, Jones C, Mackay A, James M, Hornick JL, Pereira EM, Milanezi F, Fletcher CD, Schmitt FC, Ashworth A, Reis-Filho JS: Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis. Clin Cancer Res; 2007 Jan 1;13(1):90-101
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin 1 is overexpressed and amplified in a subset of basal-like and metaplastic breast carcinomas: a morphologic, ultrastructural, immunohistochemical, and in situ hybridization analysis.
  • PURPOSE: The distribution and significance of caveolin 1 (CAV1) expression in different breast cell types and role in breast carcinogenesis remain poorly understood.
  • Both tumor-suppressive and oncogenic roles have been proposed for this protein.
  • EXPERIMENTAL DESIGN: CAV1 distribution in frozen and paraffin-embedded whole tissue sections of normal breast was evaluated using immunohistochemistry, immunofluorescence, and immunoelectron microscopy.
  • CAV1 expression was immunohistochemically analyzed in benign lesions, breast cancer precursors, and metaplastic breast carcinomas and in a cohort of 245 invasive breast carcinomas from patients treated with surgery followed by anthracycline-based chemotherapy.
  • RESULTS: In normal breast, CAV1 was expressed in myoepithelial cells, endothelial cells, and a subset of fibroblasts.
  • In the later cohort, CAV1 expression was significantly associated with 'basal-like' immunophenotype and with shorter disease-free and overall survival on univariate analysis.
  • CONCLUSIONS: The concurrent CAV1 amplification and overexpression call into question its tumor-suppressive effects in basal-like breast carcinomas.
  • [MeSH-major] Breast / metabolism. Breast Neoplasms / pathology. Breast Neoplasms / ultrastructure. Carcinoma / pathology. Carcinoma / ultrastructure. Caveolin 1 / biosynthesis. Gene Expression Regulation, Neoplastic. Immunohistochemistry / methods. In Situ Hybridization
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Immunophenotyping. Microscopy, Fluorescence. Microscopy, Immunoelectron. Neoplasm Invasiveness. Neoplasm Metastasis. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17200343.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


5. Kyriazi MA, Carvounis EE, Kitsou M, Arkadopoulos N, Nicolaidou E, Fotiou S, Smyrniotis V: Myoepithelial carcinoma of the vulva mimicking bartholin gland abscess in a pregnant woman: case report and review of literature. Int J Gynecol Pathol; 2010 Sep;29(5):501-4
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial carcinoma of the vulva mimicking bartholin gland abscess in a pregnant woman: case report and review of literature.
  • Myoepithelial tumors of the vulva are extremely rare, with only 8 cases reported in the literature to date.
  • We report the first case of a high-grade myoepithelial vulvar carcinoma diagnosed in a 35-year-old woman during the 27th week of her pregnancy.
  • However, the patient rapidly developed both locoregional and distant mestatatic disease, despite aggressive chemoradiotherapy, and she eventually succumbed to disseminated disease almost 20 months after her initial diagnosis.
  • [MeSH-major] Abscess / pathology. Bartholin's Glands / pathology. Myoepithelioma / pathology. Pregnancy Complications / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Fatal Outcome. Female. Gynecologic Surgical Procedures. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / surgery. Pregnancy. Radiotherapy

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Abscess.
  • MedlinePlus Health Information. consumer health - Health Problems in Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20736781.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Miura K, Harada H, Aiba S, Tsutsui Y: Myoepithelial carcinoma of the lung arising from bronchial submucosa. Am J Surg Pathol; 2000 Sep;24(9):1300-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myoepithelial carcinoma of the lung arising from bronchial submucosa.
  • Myoepithelial neoplasm mainly occurs in the salivary glands and breasts and is extremely rare in the lung.
  • To our knowledge, this report describes the first documented case of a myoepithelial carcinoma present in the lung.
  • The tumor derived from the right main bronchial submucosa and exhibited a dual epithelial and smooth muscular phenotype by immunohistochemical and ultrastructural studies.
  • It invaded the neighboring pulmonary tissue and the hilar lymph nodes.
  • Despite a right pneumonectomy and chemotherapy, metastasis was found in the left lung 7 months later.
  • [MeSH-major] Bronchial Neoplasms / pathology. Lung Neoplasms / pathology. Myoepithelioma / pathology. Salivary Gland Neoplasms / pathology
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10976707.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


7. Nieder C, Schneller F, Grosu AL, Peschel C, Molls M: Radiotherapy and chemotherapy for myoepithelioma of the sellar region. Strahlenther Onkol; 2005 Apr;181(4):260-3
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy and chemotherapy for myoepithelioma of the sellar region.
  • BACKGROUND: Myoepithelioma might arise in the head and neck area, especially within the salivary glands.
  • It is very uncommon as a primary intracranial tumor.
  • CASE REPORT: A 34-year-old African patient with proliferating myoepithelioma originating in the sellar region is described.
  • After subtotal resection, the tumor recurred locally despite postoperative radiotherapy to a total dose of 54 Gy (Figures 1 and 2).
  • When intracranial metastases developed, chemotherapy with ifosfamide and, later, BCNU was administered.
  • Uncontrolled intracranial tumor growth led to the patient's death 20 months after the initial diagnosis.
  • CONCLUSION: Most tumors of the sellar region have a favorable prognosis.
  • However, this case of incompletely resected proliferating myoepithelioma showed both local and distant recurrences, which did not respond to further treatment.
  • [MeSH-major] Bone Neoplasms / drug therapy. Bone Neoplasms / radiotherapy. Myoepithelioma / drug therapy. Myoepithelioma / radiotherapy. Sella Turcica / radiography
  • [MeSH-minor] Adult. Combined Modality Therapy. Fatal Outcome. Female. Humans. Palliative Care. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15827697.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


8. Sahab ZJ, Man YG, Semaan SM, Newcomer RG, Byers SW, Sang QX: Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype. Clin Exp Metastasis; 2010 Oct;27(7):493-503
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration in protein expression in estrogen receptor alpha-negative human breast cancer tissues indicates a malignant and metastatic phenotype.
  • Ductal carcinoma in situ (DCIS) represents the earliest identifiable breast cancer lesion.
  • Disruption of the myoepithelial cell layer and basement membrane is a prerequisite for DCIS to initiate invasion into the stroma.
  • The majority of epithelial cells overlying a focally-disrupted myoepithelial cell layer are estrogen receptor-alpha negative (ER(-)); however, adjacent cells within the same duct confined by an intact myoepithelial cell layer express high levels of ER.
  • The upregulated protein, Rho GDP-dissociation inhibitor 1 alpha, may induce chemotherapy resistance.
  • The significant findings are that the microdissected ER(-) cells express 12.6 times less cellular retinoic acid-binding protein 1, a protein involved in cellular differentiation, and 4.1 times less nucleoside diphosphate kinase A or nm23-H1, a metastasis suppressor, and express fewer proteins than adjacent ER(+) cells.
  • The collective role of the alterations of protein expression in ER(-) cells may be to promote a more malignant phenotype than adjacent ER(+) cells, including a decreased ability to undergo apoptosis and differentiation, and an increased potential to damage DNA, metastasize, and resist to chemotherapy.
  • [MeSH-major] Breast Neoplasms / metabolism. Estrogen Receptor alpha / metabolism. Neoplasm Metastasis


9. Li CQ, Guo ZM, Liu WW, Zhang Q, Yang AK, Yang L: [Clinical analysis of myoepithelial carcinoma of head and neck]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Feb;45(2):124-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of myoepithelial carcinoma of head and neck].
  • OBJECTIVE: To evaluate clinical feature, diagnosis, treatment and prognosis of myoepithelial carcinoma (MC) in the head and neck.
  • RESULTS: All cases were operated, 4 underwent surgery alone, 2 underwent surgery plus adjuvant radiotherapy, 2 received surgery plus adjuvant chemotherapy, 3 underwent surgery plus adjuvant chemoradiation.
  • There was spindle cell type in 5 cases, clear cell type, plasmacytoid cell type in 2 cases, epithelioid cell type, mixed type in 1 case.
  • The median follow-up time was 40 months.
  • AS to the last follow-up time, 8 patients died.
  • CONCLUSIONS: The characteristics of the tumor were rapidly enlarging, invading the surrounding regions, high rates of lymph node metastasis, high rates of distance metastasis.
  • MC was a sort of malignant tumor.
  • Chemotherapy and radiotherapy may be effective after operation.
  • [MeSH-major] Head and Neck Neoplasms. Myoepithelioma
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Prognosis. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398508.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


10. Magrini E, Pragliola A, Farnedi A, Betts CM, Cocchi R, Foschini MP: Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland. Virchows Arch; 2004 Jan;444(1):82-6
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic analysis of myoepithelial cell carcinoma of salivary gland.
  • Myoepithelial cell carcinoma (MCC) of the salivary gland is a rare entity.
  • The patient was a 53-year-old man, with a rapidly growing lesion of the palate.
  • Despite complete surgical excision, radio- and chemotherapy, the lesion rapidly harboured local and distant metastases leading to the death of the patient, 4 months after the diagnosis.
  • On histological and ultrastructural examination, the primary tumour and the related metastases were composed of oval and spindle cells, with features of myoepithelial cell differentiation reported in the literature.
  • Cytogenetic analysis showed a composite karyotype in the primary tumour: 45-46,XY, +3[cp3]/ 44-45,XY, -17[cp4]/ 46,XY[5].
  • Our cytogenetic data differ from those described in benign or slowly growing salivary gland tumours showing myoepithelial cell differentiation.
  • [MeSH-major] Chromosomes, Human, Pair 17. Cytogenetic Analysis. Monosomy. Myoepithelioma / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Calcium-Binding Proteins / analysis. Cell Differentiation. DNA-Binding Proteins. Fatal Outcome. Genes, Tumor Suppressor. Humans. Karyotyping. Keratins / analysis. Lymphatic Metastasis / pathology. Male. Microfilament Proteins. Middle Aged. Neoplasm Metastasis / pathology. Palate, Hard. Phosphoproteins / analysis. Trans-Activators / analysis. Transcription Factors. Tumor Suppressor Protein p53 / analysis. Tumor Suppressor Proteins

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Genet Cytogenet. 1986 Dec;23(4):305-13 [3022913.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Jul 15;128(2):130-6 [11463451.001]
  • [Cites] Virchows Arch. 1997 Apr;430(4):339-42 [9134046.001]
  • [Cites] Virchows Arch. 2002 Nov;441(5):428-36 [12447671.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):49-53 [10459346.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Feb;109(1):66-9 [9973962.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2314-9 [9191518.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Feb;30(2):161-7 [11135432.001]
  • [Cites] Lab Invest. 2000 Jun;80(6):831-6 [10879734.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):761-74 [10843278.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • (PMID = 14994730.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / DNA-Binding Proteins; 0 / Microfilament Proteins; 0 / Phosphoproteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; 0 / calponin; 68238-35-7 / Keratins
  •  go-up   go-down


11. Mainka P, Kahlert S, Kirchner T, Mayr D, Diebold J: [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?]. Pathologe; 2008 Nov;29 Suppl 2:363-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal and myoepithelial phenotype of metastatic mammary carcinomas. A prognostic factor in the palliative situation?].
  • [Transliterated title] Basaler und myoepithelialer Phänotyp des invasiven Mammakarzinoms. Prognostischer Faktor in der palliativen Situation?
  • AIMS: The aim of the present study was to evaluate the prognostic impact of basal and myoepithelial phenotype in breast carcinomas (BBC and MBC) in the palliative situation.
  • METHODS: Paraffin-embedded material from 244 primary breast carcinomas of patients with subsequent metastatic disease was stained immunohistochemically for CK 5/6, CK14, smooth-muscle actin, p63, estrogen receptor and progesterone receptor.
  • This subgroup, but not BBC or MBC was an independent negative prognostic factor in a multivariate analysis including age, typing, tumour size, grading, axillary nodes, HR, Her2/neu, site of first metastasis and disease-free interval.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / pathology. Carcinoma, Ductal / pathology. Carcinoma, Lobular / pathology. Myoepithelioma / pathology. Neoplasms, Hormone-Dependent / pathology. Palliative Care. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis
  • [MeSH-minor] Breast / pathology. Female. Humans. In Situ Hybridization, Fluorescence. Keratin-14 / analysis. Keratin-5 / analysis. Keratin-6 / analysis. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Second Primary / drug therapy. Neoplasms, Second Primary / mortality. Neoplasms, Second Primary / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Clin North Am. 1999 Oct;79(5):1117-43 [10572554.001]
  • [Cites] Breast Cancer Res Treat. 1992;21(3):173-80 [1515652.001]
  • [Cites] Cancer. 1992 Jul 1;70(1):129-35 [1606535.001]
  • [Cites] J Pathol. 2006 Mar;208(4):495-506 [16429394.001]
  • [Cites] Breast Cancer Res Treat. 2003 Nov;82(2):83-92 [14692652.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4185-91 [16857790.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):358-73 [17717437.001]
  • [Cites] J Clin Oncol. 1987 Jan;5(1):55-61 [3806159.001]
  • [Cites] Lancet. 1987 Feb 28;1(8531):514 [2881076.001]
  • [Cites] Cancer. 2004 May 1;100(9):1833-42 [15112263.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R4 [17217540.001]
  • [Cites] BMC Cancer. 2007 Jul 24;7:134 [17650314.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1991-6 [12466114.001]
  • [Cites] Virchows Arch. 1998 Aug;433(2):119-29 [9737789.001]
  • [Cites] Breast Cancer Res. 2007;9(1):R16 [17263897.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Feb;20(1):40-5 [17981444.001]
  • [Cites] Cancer. 2003 Feb 1;97(3):545-53 [12548595.001]
  • [Cites] J Clin Oncol. 2000 Nov 1;18(21):3651-64 [11054438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • (PMID = 18807040.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-14; 0 / Keratin-5; 0 / Keratin-6; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


12. Shao ZM, Radziszewski WJ, Barsky SH: Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms. Cancer Lett; 2000 Sep 1;157(2):133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms.
  • Our previous studies have indicated that myoepithelial cells surrounding ductal and acinar epithelium of glandular organs, such as the breast, exert multiple paracrine suppressive effects on incipient and developing cancers that arise from this epithelium.
  • Myoepithelial cells and derived cell lines (HMS 1-6) exert these effects through the secretion of a number of different effector molecules that exert anti-invasive, anti-proliferative, and anti-angiogenic activities.
  • Since previous basic and clinical studies have examined the role of estrogen agonists and antagonists on human breast cancer cells and because issues of hormone replacement therapy (HRT) and tamoxifen chemoprevention are such timely issues in breast cancer, we wondered whether or not hormonal manipulations might affect myoepithelial cells in vitro as far as their paracrine suppressive activities on breast cancer were concerned.
  • The present in vitro study demonstrates that treatment of myoepithelial cells with tamoxifen but not 17beta-estradiol increases both maspin secretion and invasion-blocking ability.
  • Furthermore tamoxifen but not 17beta-estradiol increases inducible nitric oxide synthase (iNOS) expression and nitric oxide (NO) production by myoepithelial cells when they are co-cultured with conditioned media from or breast carcinoma cells directly.
  • This increased myoepithelial NO exerts both autocrine and paracrine antiproliferative effects which can be blocked by inhibition of iNOS.
  • Myoepithelial cells lack ER-alpha but express ER-beta.
  • These experiments collectively suggest that the actions of tamoxifen on the increased secretion of maspin and increased production of NO by myoepithelial cells are mediated through ER-beta and the transcription-activation of an ER-dependent AP-1 response element.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Estrogen Antagonists / pharmacology. Tamoxifen / pharmacology
  • [MeSH-minor] Blotting, Northern. Blotting, Western. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / metabolism. Cell Division / drug effects. Disease Progression. Epithelial Cells / drug effects. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neovascularization, Pathologic / prevention & control. Nitric Oxide / biosynthesis. Nitric Oxide Synthase / biosynthesis. Nitric Oxide Synthase Type II. Precipitin Tests. Proteins / drug effects. Proteins / secretion. Reverse Transcriptase Polymerase Chain Reaction. Serine Proteinase Inhibitors / secretion. Serpins / drug effects. Serpins / secretion. Time Factors. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Myoepithelial carcinoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10936673.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 71195; United States / NCI NIH HHS / CA / CA 83111
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] IRELAND
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Estrogen Antagonists; 0 / Proteins; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins; 094ZI81Y45 / Tamoxifen; 31C4KY9ESH / Nitric Oxide; EC 1.14.13.39 / NOS2 protein, human; EC 1.14.13.39 / Nitric Oxide Synthase; EC 1.14.13.39 / Nitric Oxide Synthase Type II
  •  go-up   go-down


13. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H, European Working Group for Breast Screening Pathology, Breast Cancer Linkage Consortium: Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol; 2005 Nov;207(3):260-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Typical medullary breast carcinomas have a basal/myoepithelial phenotype.
  • MBC patients have an excess of BRCA1 germ-line mutation and reliable identification of MBC could help to identify patients at risk of carrying germline BRCA1 mutations or in whom chemotherapy could be avoided.
  • The aim of this study was therefore to improve diagnosis by establishing an MBC protein expression profile using immunohistochemistry (IHC) on tissue-microarrays (TMA).
  • TMBC was characterized by a high degree of basal/myoepithelial differentiation.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Medullary / diagnosis. Neoplasm Proteins / analysis
  • [MeSH-minor] Cadherins / genetics. Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Female. Gene Expression Regulation, Neoplastic / genetics. Genes, BRCA1. Genes, erbB-2 / genetics. Humans. Immunohistochemistry / methods. Keratins / genetics. Ki-67 Antigen / genetics. Mutation / genetics. Phenotype. Protein Array Analysis / methods. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 16167361.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cadherins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53; 68238-35-7 / Keratins
  •  go-up   go-down


14. Huang R, Jaffer S: Imprint cytology of metastatic sialoblastoma. A case report. Acta Cytol; 2003 Nov-Dec;47(6):1123-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sialoblastoma is a rare, aggressive and potentially malignant perinatal/congenital tumor that recapitulates the developing salivary gland.
  • CASE: A 75-month-old girl with a history of recurrent sialoblastoma initially diagnosed at 21 months and treated with multiple incomplete surgical excisions, chemotherapy and radiation presented with a solitary lung nodule.
  • CONCLUSION: Cytologic features of sialoblastoma showed complete concordance with histology and included the presence of variably arranged, tight, solid clusters of atypical-appearing, basaloidlike cells in a background of dispersed epithelial and myoepithelial cells.
  • The differential diagnoses include neoplasms composed of either basaloid cells and/or admixed hyaline matrix material and included pleomorphic adenoma, basal cell adenoma and adenoid cystic carcinoma.
  • [MeSH-major] Carcinoma, Adenoid Cystic / secondary. Lung Neoplasms / secondary. Neoplasms, Germ Cell and Embryonal / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Diagnosis, Differential. Disease Progression. Epithelial Cells / pathology. Female. Humans. Neoplasm Metastasis / pathology. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Parotid Gland / pathology. Parotid Gland / surgery. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14674095.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Lee JR, Georgi DE, Wang BY: Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature. Ann Diagn Pathol; 2007 Jun;11(3):190-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant myoepithelial tumor of soft tissue: a report of two cases of the lower extremity and a review of the literature.
  • Myoepithelial tumors of the soft tissues have only recently been described.
  • Two cases of lower extremity malignant myoepithelial tumors are reported.
  • One case of malignant mixed tumor overlying the gastrocnemius muscle was treated with wide local excision, but metastasized to regional lymph nodes 14 months after surgical excision.
  • One patient with malignant myoepithelioma of the right lower leg was treated with limb amputation and is alive without disease at 46 months.
  • A review of the literature discloses 120 additional cases of soft tissue myoepithelial tumors, 102 of which are myoepitheliomas and 18 are mixed tumors.
  • Thirty-seven percent of the myoepitheliomas met the criteria for malignancy, and 33% of the mixed tumors were malignant.
  • Of these, 30% had locally recurrent disease and 32% developed metastatic disease.
  • Treatment benefit from chemotherapy and radiation therapy is unclear.
  • [MeSH-major] Myoepithelioma / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Calcium-Binding Proteins / metabolism. Cell Proliferation. Glial Fibrillary Acidic Protein / metabolism. Humans. Leg / pathology. Male. Microfilament Proteins / metabolism. Middle Aged. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Malignant / pathology. Necrosis / pathology. Phosphopyruvate Hydratase / metabolism. Vimentin / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498593.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Glial Fibrillary Acidic Protein; 0 / Microfilament Proteins; 0 / Vimentin; 0 / calponin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Number-of-references] 35
  •  go-up   go-down


16. Zhou SH, Ruan LX, Gong L, Wang SQ: Primary malignant myoepithelioma of the left maxillary sinus: a case report. J Int Med Res; 2008 Mar-Apr;36(2):362-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant myoepithelioma of the left maxillary sinus: a case report.
  • We describe the case of a 41-year-old woman who presented with a malignant myoepithelioma (MME) in her left maxillary sinus.
  • Exploratory biopsy of the left maxillary sinus was performed and pathological examination demonstrated that the tumour was positive for calponin and cytokeratin 14, which are indicative of MME.
  • Lateral rhinotomy and left total maxillectomy were undertaken and the patient received radiotherapy and chemotherapy post-surgery.
  • [MeSH-major] Maxillary Sinus Neoplasms / diagnosis. Myoepithelioma / diagnosis
  • [MeSH-minor] Adult. Calcium-Binding Proteins / analysis. Fatal Outcome. Female. Humans. Keratin-14 / analysis. Microfilament Proteins / analysis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380949.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Keratin-14; 0 / Microfilament Proteins; 0 / calponin
  •  go-up   go-down


17. Weigelt B, Kreike B, Reis-Filho JS: Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat; 2009 Sep;117(2):273-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metaplastic breast carcinomas (MBCs) comprise a group of aggressive and chemotherapy resistant cancers characterised by neoplastic cells displaying differentiation towards squamous epithelium or mesenchymal elements.
  • Pathway analysis using these genes revealed that DNA repair pathways, including BRCA1 pathway, PTEN, a gene whose loss of function is associated with resistance to chemotherapy, and TOP2A, the molecular target of anthracyclines, are significantly downregulated in MBCs compared to basal-like IDCs.
  • These findings may at least in part explain the reported poor responses to chemotherapy of MBCs.
  • Furthermore, MBCs showed significantly higher expression of genes related to myoepithelial differentiation and epithelial to mesenchymal transition (EMT).
  • CONCLUSIONS: Our results demonstrate that MBCs are part of the spectrum of basal-like breast carcinomas and display a myoepithelial and EMT-like molecular make-up.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Gene Expression Profiling
  • [MeSH-minor] Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. DNA Topoisomerases, Type II / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / genetics. DNA-Binding Proteins / metabolism. Down-Regulation. Female. Humans. Immunohistochemistry. Metaplasia. Oligonucleotide Array Sequence Analysis. PTEN Phosphohydrolase / genetics. PTEN Phosphohydrolase / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18815879.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


18. Trepp R, Padberg BC, Varga Z, Cathomas R, Inauen R, Reinhart WH: Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation. Pathol Res Pract; 2010 May 15;206(5):334-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive extranodal metastases of basal-like breast cancer with predominant myoepithelial spindle cell differentiation.
  • A differentiation towards myoepithelial cells has been demonstrated in several types of lesions in the breast.
  • These include multifocal myoepitheliomatosis, the rare mixed tumor or pleomorphic adenoma, adenoid cystic carcinoma, adenomyoepithelioma and myoepithelial carcinoma (malignant myoepithelioma).
  • Myoepithelial carcinoma is the only lesion purely composed of myoepithelial cells.
  • All these tumors are benign and/or of low-grade malignancy, with the exception of malignant myoepithelioma.
  • In contrast to the statement of the current World Health Organization (WHO), recent studies have reported that regional and distant metastases may occur in about 50% of pure myoepithelial carcinomas.
  • The presented case of a breast carcinoma with dominant myoepithelial/spindle cell differentiation in a 58-year-old woman is an excellent example to document the highly aggressive biological behavior of this tumor phenotype.
  • Despite an extensive chemotherapy and radiotherapy, the tumor was rapidly progressive, forming a finally exulcerating local tumor relapse and widespread metastases to the myocardium, lungs, liver, kidneys and skin.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / secondary. Kidney Neoplasms / secondary. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Skin Neoplasms / secondary
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Transformation, Neoplastic / pathology. Fatal Outcome. Female. Humans. Middle Aged


19. Yu T, Gao QH, Wang XY, Wen YM, Li LJ: Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases. Oncology; 2007;72(1-2):39-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant sublingual gland tumors: a retrospective clinicopathologic study of 28 cases.
  • OBJECTIVES: To evaluate the clinicopathologic features and therapeutic efficacy of malignant sublingual gland tumors.
  • RESULTS: There were 16 males and 12 females, with a mean age of 50.3 years.
  • Eighteen cases (64.3%) were adenoid cystic carcinoma; 16 (57.1%) cases were clinically staged as III-IV.
  • Adenoid cystic carcinoma was mainly of the histologic type, and the other histologic classifications included mucoepidermoid carcinoma, myoepithelial carcinoma, polymorphous low-grade adenocarcinoma, adenocarcinoma and malignant pleomorphic adenoma.
  • Pulmonary metastasis and tumor recurrence were the main death reasons.
  • Eleven patients remain alive and well 34-312 months (median 108) after treatment.
  • CONCLUSIONS: Malignant sublingual gland tumors are extremely rare and most are adenoid cystic carcinoma.
  • Surgery is the main treatment option.
  • For adenoid cystic carcinoma, hematogenous spread is common, and pulmonary metastasis is a common pathway of the distant metastasis.
  • Postoperative radiation therapy may be adjuvant for selected patients with high-stage and high-grade tumors, or when there is concern about the inadequacy of the resection.
  • The effect of chemotherapy remains elusive.
  • [MeSH-major] Carcinoma, Adenoid Cystic / pathology. Sublingual Gland Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Humans. Lung Neoplasms / mortality. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Recurrence, Local / mortality. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 S. Karger AG, Basel.
  • (PMID = 17998789.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


20. Fadare O, Tavassoli FA: Clinical and pathologic aspects of basal-like breast cancers. Nat Clin Pract Oncol; 2008 Mar;5(3):149-59
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gene-expression profiling of breast cancers has shown that distinct molecular subclasses are present within tumors that are apparently morphologically similar.
  • The molecular subclasses of cohorts classified by the 'intrinsic' gene set include the luminal A and B, erbB-2+, normal-breast-like, and basal-like tumors.
  • Basal-like breast cancers have been reported to be associated with worse overall and disease-free survival compared with the luminal A subtype.
  • Basal-like breast carcinomas have markedly reduced expression of genes related to estrogen receptors and erbB-2, and express proteins that are characteristic of the normal myoepithelial cell.
  • These tumors seem to be relatively heterogeneous according to a multitude of clinicopathologic parameters, which indicates that their most prognostically relevant subsets have yet to be defined.
  • Similarly to tumors of luminal epithelial differentiation, carcinomas of the 'basal' type have a spectrum of morphologic and clinical characteristics.
  • [MeSH-minor] Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / pathology. Female. Gene Expression Profiling. Genes, BRCA1. Germ-Line Mutation. Humans. Neoplasm Invasiveness. Neoplasms, Basal Cell / drug therapy. Neoplasms, Basal Cell / genetics. Neoplasms, Basal Cell / pathology. Phenotype. Prognosis. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18212769.001).
  • [ISSN] 1743-4262
  • [Journal-full-title] Nature clinical practice. Oncology
  • [ISO-abbreviation] Nat Clin Pract Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 100
  •  go-up   go-down


21. Wu Q, Liu C, Lei L, Yan X, Wang B, Liu X, Yv L, Lv Y: Interdigitating dendritic cell sarcoma involving bone marrow in a liver transplant recipient. Transplant Proc; 2010 Jun;42(5):1963-6
MedlinePlus Health Information. consumer health - Liver Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver transplantation is an effective treatment for patients with many kinds of liver diseases.
  • However, an increased risk of de novo malignancy has been reported in liver transplant recipients; immunosuppressive drugs have generally been identified as the primary culprit.
  • Interdigitating dendritic cell sarcoma (IDCS) is an exceedingly rare neoplasm arising from antigen-presenting cells of the immune system.
  • In this study, we have reported a case of IDCS with bone marrow involvement occurring in a 61-year-old female liver transplant recipient at 2 years after the procedure.
  • Computerized tomography of the chest, abdomen, and pelvis were negative.
  • Microscopically, the tumor was composed of spindle cells with pale to eosinophilic cytoplasm, ill-defined cell borders, and large pleomorphic nuclei with prominent nucleoli.
  • Follicular dendritic cell, lymphoid, epithelial, myoepithelial, and melanoma markers were negative.
  • She responded to chemotherapy.
  • This case demonstrates the importance of cancer prevention and early detection for liver transplant recipients.
  • [MeSH-major] Bone Marrow / pathology. Carcinoma, Hepatocellular / surgery. Dendritic Cell Sarcoma, Interdigitating / complications. Liver Neoplasms / surgery. Liver Transplantation / methods
  • [MeSH-minor] Female. Hepatitis B / complications. Humans. Liver Cirrhosis / surgery. Liver Cirrhosis / virology. Lymph Nodes / pathology. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620556.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Carter MR, Hornick JL, Lester S, Fletcher CD: Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases. Am J Surg Pathol; 2006 Mar;30(3):300-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell (sarcomatoid) carcinoma of the breast: a clinicopathologic and immunohistochemical analysis of 29 cases.
  • Spindle cell (sarcomatoid) carcinoma of the breast is a rare variant of breast cancer that has been classified under the broad rubric of metaplastic carcinoma.
  • Because the term "metaplastic carcinoma" comprises a heterogeneous group of tumors, it has been difficult to reliably predict biologic potential or to determine optimal therapy.
  • Tumor size ranged from 1.5 to 15 cm (median, 4 cm).
  • Treatment was by excision and/or mastectomy with axillary node evaluation in most cases, often combined with postoperative radiation and/or chemotherapy.
  • All cases were clinically of breast origin, showed >or=80% spindled/sarcomatoid morphology, and demonstrated keratin positivity and/or close association with ductal carcinoma in situ.
  • Immunohistochemical studies showed evidence suggesting myoepithelial differentiation as exhibited by immunoreactivity for smooth muscle actin, cytokeratin 14, and p63 in a subset of cases (39%).
  • Twenty-seven cases exhibited pure spindled or sarcomatoid morphology of variable appearance and nuclear grade, whereas 2 contained high-grade invasive ductal carcinoma comprising <or=20% of the tumor mass.
  • Two cases exhibited heterologous elements (1 rhabdomyosarcoma and 1 with both chondrosarcoma and osteosarcoma) and 4 were associated with ductal carcinoma in situ.
  • Of 20 cases in which axillary nodes were biopsied, definitive nodal metastases were identified in only 1 (5%), and this was in a case with a significant component of invasive ductal carcinoma.
  • Three patients developed local recurrences.
  • Ten of 24 patients (42%) died of disease at a median interval of 11.5 months (range, 1-46 months) and 3 patients were alive with metastatic disease.
  • Eight patients were alive with no evidence of recurrent or metastatic disease (median, 29.5 months).
  • Based on this series, spindle cell/sarcomatoid carcinoma of the breast is a highly aggressive neoplasm with a high rate of extranodal metastases.
  • Purely spindled/sarcomatoid tumors have a significantly lower rate of nodal metastases than conventional ductal and lobular breast carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2007 Feb;31(2):326-7; author reply 327 [17255781.001]
  • (PMID = 16538049.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down






Advertisement